Clinical trials: Attention Deficit Hyperactivity Disorder Symptoms
- Condition Attention Deficit Hyperactivity Disorder Symptoms
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
- Trial name
- NCT03327402
- Testing
- SHP465
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at 6.25 milligram (mg) in children aged 4 to 12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03325894
- Testing
- SHP465
- Where
- 48 sites in United States
- Volunteers
- 141 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a…
- Trial name
- NCT00419445
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- CoMentis
ADHD
An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms
The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- A-GAMES (NCT05805176)
- Testing
- ADHD Therapy
- Where
- 5 sites in United States
- Volunteers
- 194 people
- Sponsor
- Lumos Labs, Inc.
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, impulsivity, and impaired executive functioning.
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type, ADHD
- Trial name
- NCT07173439
- Testing
- Model Name: EMT-SR01;red
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- EMOTIV
Attention Deficit Hyperactivity Disorder, Cannabis Abuse
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
- Trial name
- PEACE (NCT00687609)
- Testing
- Atomoxetine
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
ADHD
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
- Trial name
- NCT00367835
- Testing
- SPD503 (Guanfacine hydrochloride)
- Where
- 34 sites in United States
- Volunteers
- 217 people
- Sponsor
- Shire
Phenylketonuria
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.
- Trial name
- NCT01114737
- Testing
- Sapropterin dihydrochloride
- Where
- 36 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- BioMarin Pharmaceutical
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit/Hyperactivity Disorder
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
- Trial name
- NCT01338818
- Testing
- Ritalin LA (methylphenidate hydrochloride extended release)
- Where
- 48 sites in United States, Belgium and 4 more
- Volunteers
- 299 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to determine if an investigational treatment is effective in improving the total score on the ADHD-RS-IV Preschool Version in children 4-5 years old diagnosed with ADHD.
- Trial name
- NCT03260205
- Testing
- SPD489 (Lisdexamfetamine dimesylate), SPD489
- Where
- 48 sites in United States
- Volunteers
- 199 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients
The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.
- Trial name
- NCT00664703
- Testing
- Lobeline sulfate, Methylphenidate HCl
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yaupon Therapeutics
ADHD
Guided ADHD Therapy for Managing the Extent and Severity of Symptoms
The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- GAMES (NCT05296473)
- Testing
- ADHD Therapy, Control Therapy
- Where
- 13 sites in United States
- Volunteers
- 560 people
- Sponsor
- Lumos Labs, Inc.
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.